Tiago Biachi @BiachiTiago Twitter profile

Last Seen Profiles

@BridgesClips

@OofGoofy

@Lavendertears33

@ESBonchamp

@javipdr

@seaman_139520

@CaravanAOM

@roikamiskiya

@DonyPatrin52632

@homare_works

@giovanababie

@kazuha16269673

@AlsamraBasm

@TravisEHughes

@s2_hana_s200524

@GangSter42878

@larahgba

@por_ni_556

@Fahadalimafiya

@longliveboonie

@w99if

@NeoArtCoRe

@asadaeri192120

@kina__1967

@stwmaniax

@MyBnkNorthWest

@BlkMultiverse

@IspynArt

@CSUPsoftball

@sachannnn_yj

@ppichchi41713

@pitikcilik94

@realCraigA

@AhRelevant

@JherovyF

@yukiworkingmom

Tiago Biachi

@BiachiTiago

2 months

The most exciting achievement I've ever had, I've been promoted to a DAD!

34

10

607

Tiago Biachi

@BiachiTiago

3 years

CAR-T cell therapy is coming to stay for solid tumors… 61% ORR in 3L for #gastriccancer in ph1 trial is really promising!! @myESMO @OncoAlert

2

63

255

Tiago Biachi

@BiachiTiago

2 years

I am thrilled to announce that I am joining @MoffittNews as Medical Oncologist - Associate Member at Gastrointestinal Medical Oncology Department. Grateful for all my colleagues and mentors in Brazil and US.

24

7

247

Tiago Biachi

@BiachiTiago

2 years

Unbelievable data presented by @AndreaCercek with 100% CR for MSI rectal cancer with dostarlimab. No surgery, no chemo, no radiation and NO CANCER! Congrats you all! @AndreaCercek @LumishMelissa , Luiz Diaz and @MSKCancerCenter team! @OncoAlert #asco22

1

42

159

Tiago Biachi

@BiachiTiago

2 years

Driving to our next home, full loaded with suitcases and dreams. Thanks NY and @MSKCancerCenter for everything.

3

2

117

Tiago Biachi

@BiachiTiago

2 years

This is not a waterfall plot, we need another name for this! Congrats @MyriamChalabi 👏🏼👏🏼👏🏼 @myESMO #ESMO22

6

10

88

Tiago Biachi

@BiachiTiago

2 years

#ASCO22 NICHE trial in localized #CRC treated with neoadjuvant short course of NIVO+IPI: ✅ 97% of major path response in MSI ✅ 30% of path response in MSS (including 3 pCR) ⁉️Lot to learn from these MSS cases ❗️Bright solutions are coming up for MSI @OncoAlert

2

18

83

Tiago Biachi

@BiachiTiago

2 years

CAPOX 3 months, CAPOX 3 months, CAPOX 3 months! #colorectalcancer Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients...

PURPOSEThe combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal...

ascopubs.org

1

19

80

Tiago Biachi

@BiachiTiago

2 years

Here, few interesting abstracts in GI that are going to be presented at #ESMO22 1) MOONLIGHT Ph2 trial showed inferior outcomes with sequential FOLFOX->nivo/IPI compared to concurrent FOLFOX/nivo/ipi. However, AE G ≥3 were seen in 93% and SAE in 70% with concurrent strategy.

1

20

71

Tiago Biachi

@BiachiTiago

3 years

Merry Christmas and a Happy New Year filled with love, compassion, health and peace to everyone!

0

60

Tiago Biachi

@BiachiTiago

2 years

#ASCO22 @michael_overman CheckMate 142 in MSI #CRC : Impressive data from the small cohort 3 (1L; NIVO3 Q2W+IPI1 Q6W): ✅ ORR 71% ✅ 48-mo PFS 51% ✅ Median PFS and OS NR ✅ G3-4 tox 80% (~ other cohorts)

2

17

52

Tiago Biachi

@BiachiTiago

2 years

Adjuvant GemCis vs cape for LN+ extra hepatic CCA phase 2 STAMP trial: ✅ DFS 14.3 vs 11.1 mo (HR=0.96,p=0.8) ✅ OS 35.7 vs 35.7 mo (HR=1.08,p=0.8) ✅ G3-4 AE 84% vs 16% ✳️ GemCis more toxic and did not improve outcomes ✳️ Waiting for ATTICA-1 trial data @OncoAlert #ASCO22

4

10

50

Tiago Biachi

@BiachiTiago

4 years

70℅ of 6m-PFS mEGA is amazing! Congrats @YJanjigianMD

1

8

42

Tiago Biachi

@BiachiTiago

2 years

FOX interview earlier today discussing #ColorectalCancerAwarenessMonth 1/3 US pop. eligible for a colonoscopy never had one. 1/3 US pop. is outdated with colonoscopy… We can do much better! @MoffittNews @USFNews

2

4

39

Tiago Biachi

@BiachiTiago

2 years

NALIRIFOX improved OS vs GemNab in NAPOLI 3 trial. Looking forward to see these numbers. #PancreaticCancer @OncoAlert @MoffittNews

1

10

38

Tiago Biachi

@BiachiTiago

2 years

To wrap up my first week as attending in US I got this beautiful surprise! So proud to be here @MoffittNews !

2

0

37

Tiago Biachi

@BiachiTiago

1 year

Thanks @PatrickHwuMD ! It's an honor and a privilege to be part of an organization that deeply cares about its employees and empowers our patients and their families to be part of their healthcare experience. @MoffittNews

Dr. Patrick Hwu

@PatrickHwuMD

1 year

Dr. Tiago Biachi is a medical oncologist and associate member in the Department of Gastrointestinal Oncology @MoffittNews ! Go give him a follow @BiachiTiago ! #FollowFriday

5

0

35

1

35

Tiago Biachi

@BiachiTiago

1 year

Brazilian team in the first soccer tournament at #ASCO2023 . Congrats Argentina, we’ll see you next year on finals again!😜 Thanks @DrChoueiri for the organization!

3

2

34

Tiago Biachi

@BiachiTiago

3 years

What amazing curves! HIMALAYA trial showed 2.6 OS gain with T300+D vs sorafenib. New SOC presented by @GABOUALFA at #gi22

0

6

29

Tiago Biachi

@BiachiTiago

3 years

Starting the day with good news…Passed on step 3 #usmle 😅

1

0

31

Tiago Biachi

@BiachiTiago

3 years

What a amazing discussion regarding Primary End Point of Progression-Free Survival and Biased Evaluation in Cancer Drug Trials via @JAMAOnc part of @JAMANetwork by Ian Tannock @OncoAlert

Primary End Point of Progression-Free Survival and Biased Evaluation in Cancer Drug Trials

This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality...

jamanetwork.com

0

3

29

Tiago Biachi

@BiachiTiago

2 years

It seems that mailing letters is not enough for #colorectal cancer screening…

2

3

29

Tiago Biachi

@BiachiTiago

2 years

Less is more in #crc oral abstracts #asco22 ✅ don’t resect the asymptomatic primary tumor in stage IV ✅ don’t use triplet with anti-EGFR ✅ don’t use CT plus a ti-EGFR continuously (in asymptomatic) @OncoAlert

1

5

28

Tiago Biachi

@BiachiTiago

2 years

Amazing days with family in Orlando

0

29

Tiago Biachi

@BiachiTiago

2 years

Time to pause oncology&ASCO stuff to enjoy our families here in NYC

0

1

29

Tiago Biachi

@BiachiTiago

2 years

Best of ASCO 2022! Will discuss most relevant presentations in GI oncology at @BrasilOncologia

0

26

Tiago Biachi

@BiachiTiago

3 years

Several patients come to clinic with advanced pancreatic cancer asking why don't we try immunotherapy even w/o response predictors... here are the @EileenMOReilly ‘s answers (one of the most brilliant pancreatic cancer specialist in my opinion)

2

7

27

Tiago Biachi

@BiachiTiago

4 years

This week's presentation for Global Fellows Conference... almost done! @GABOUALFA @YJanjigianMD @Gustavo40678803 @sloan_kettering @hsiriolibanes

0

1

26

Tiago Biachi

@BiachiTiago

4 years

Must read in times of immunotherapy trials in gastroesophageal tumors using multiple endpoints...

1

25

Tiago Biachi

@BiachiTiago

3 years

CheckMate data on #esmo . Nivo/IPI arm didn’t significantly improve OS versus chemo in first line #gastriccancer . Chemo/nivo arm remain SOC worldwide for CPS > 5. Congrats @YJanjigianMD and all investigators! Huge step forward! @myESMO @OncoAlert

0

7

25

Tiago Biachi

@BiachiTiago

3 years

First, do no harm. No benefit of adding oxaliplatin in elderly with metastatic #colorectal cancer

ILSON David

@ILSONDavid

3 years

No PFS or OS benefit for adding oxaliplatin to FU BEV in elderly M1 colorectal cancer. Congratulations to our Japanese colleagues who continue to guid us to do no harm.

4

31

118

0

7

22

Tiago Biachi

@BiachiTiago

2 years

FOENIX-CCA2 phase 2 trial: Futibatinib for iCCA with FGFR2 fusion/rearrang and PD ≥1L ✅ ORR 41.7% ✅ mDOR 9.5 mo ✅ mPFS was 8.9 mo, ✅ 12mo PFS 35.4% ✅ mOS 20.0 ✅ 12mo OS 73.1% ~ population of Pemigatinib and Infigratinib Next? study co-alterations and MoR! #ASCO22

1

6

25

Tiago Biachi

@BiachiTiago

3 years

Ramadan Kareem to all Muslim friends around the globe!🙏🏼 #RamadanMubarak

0

1

24

Tiago Biachi

@BiachiTiago

5 years

I am thrilled! My IIT is almost open! Durvalumab for unresectable esophageal SCC following CRT!

0

2

24

Tiago Biachi

@BiachiTiago

5 years

Retrospective data: No benefit for adjuvant CT or CRT in MSI or EBV pos GC pts. Huge benefit in those with p53 aberrant expression with IHC...

1

5

24

Tiago Biachi

@BiachiTiago

2 years

7) Exploratory analysis from DYNAMIC study in stage II CRC: among pts with positive post-op ctDNA, 6.5% among those converted to negative ctDNa recurred compared to 71% for those who remained ctDNA positive. ctDNA more sensitive for predicting distant than locoreg recurrences.

1

5

24

Tiago Biachi

@BiachiTiago

3 years

Launch event of Nivolumab for gastroesophaeal cancer in Brazil on Nov/06. @YJanjigianMD @Gustavo40678803

0

2

21

Tiago Biachi

@BiachiTiago

11 months

Happy Thanksgiving!

1

0

20

Tiago Biachi

@BiachiTiago

3 years

Thankful for having all my loved ones in Brazil healthy! #HappyThanksgiving2021

1

22

Tiago Biachi

@BiachiTiago

8 months

Honored for being nominated Captain for Colorectal cancer at @FLASCO_ORG Looking forward to working together, spreading the word about prevention, research, novel therapies, targets and minority populations! @MoffittNews @CrcTrialsChat @CCAlliance @FightCRC

0

1

22

Tiago Biachi

@BiachiTiago

2 years

Ph3 adjuvant HAIC-FOLFOX for resected HCC MVI+: ✅DFS 27.0 vs 11.3 months ✅3yDFS rates 44.3% vs 24.2% ❇️HAIC really works for HCC ❇️IO trials ongoing and we will have to gather all data #ASCO22 @OncoAlert

1

5

22

Tiago Biachi

@BiachiTiago

2 years

#ASCO22 SEQUENCE ph2 trial: provocative data on sequential nab-P/Gem-FOLFOX vs FOLFOX for met #PDAC #pancreaticcancer : ✅ 12mo OS 55% vs 35% ✅ 12mo OS 22% vs 7% ✅ Median OS 13.2 vs 9.7 months ✅ More hem tox. with seq. regimen @OncoAlert @MSKCancerCenter

0

2

21

Tiago Biachi

@BiachiTiago

3 years

After sidedness data in CRC… a poster in #GI22 discussing “sidedness” in #pancreaticcancer 😱

0

3

22

Tiago Biachi

@BiachiTiago

3 years

Now Brazilian EGC pts have access to IO in first line and adjuvant settings.. Nivolumab launch event this morning #gastriccancer #Immunotherapy @YJanjigianMD

0

20

Tiago Biachi

@BiachiTiago

5 years

Upper GI session with @ILSONDavid at II Brazilian Oncology Week!

1

0

21

Tiago Biachi

@BiachiTiago

5 years

INTERSECTIONS 2019: Sirio-Libanes Hospital and MSKCC Meeting! Upper GI Section! @hsiriolibanes @sloan_kettering

3

1

20

Tiago Biachi

@BiachiTiago

4 years

My summary of #ASCOGI21 #GI21 for HBP cancer 1.Alliance A021501: FOLFIRINOX x8 was superior to FOLFIRINOX followed by RT in borderline PADC in 18mOS (68 vs 47%) and R0 resection (42 vs 25%).

1

4

21

Tiago Biachi

@BiachiTiago

3 years

TOPAZ trial: 685 pts with BTC randomized,huge effort, and now the new SOC with 1.3 months gain in OS. Important step forward (first since 2010) but biomarkers still needed… #gi22

0

3

20

Tiago Biachi

@BiachiTiago

3 years

Interim data from KN811 is out in @Nature . New SOC and set the bar so high for HER2+ #gastriccancer . Congrats @YJanjigianMD , so grateful to work with you at @sloan_kettering at this turning point time!

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Nature - Interim analysis of a phase III clinical trial of HER2-positive gastric adenocarinoma shows pembrolizumab plus trastuzumab and chemotherapy improves response rates compared with...

www.nature.com

0

5

20

Tiago Biachi

@BiachiTiago

1 year

A brilliant new era is about to start for Moffitt! Thrilled to be here!

Moffitt Cancer Center

@MoffittNews

1 year

“In just 12 days, we will be welcoming the first patients through those doors – all while ushering in a new era of hope in the fight against cancer. I couldn’t be prouder of our Moffitt team and our partners who have dedicated their time to ensuring a successful opening of this

3

4

38

0

20

Tiago Biachi

@BiachiTiago

4 years

Now recruiting.. DESC trial... My IIT for unresectable ESCC with durvalumab following definitive CRT without cCR..

0

2

20

Tiago Biachi

@BiachiTiago

2 years

CONKO-007 ph3 trial: CRT 50.4Gy+Gem after CT vs CT alone for LA-PDAC: ✅CRT did not improve PFS/OS ✅Higher R0/CRM- resect. rate and pCR ✳️Benefit in resect. did not translate in survival ✳️Need more translational data to guide, high risk of distant failure @OncoAlert #ASCO22

0

4

19

Tiago Biachi

@BiachiTiago

4 years

Webinar tomorrow... Immunotherapy in esophageal cancer with @YJanjigianMD and @RachelRiechelm2

0

2

20

Tiago Biachi

@BiachiTiago

2 years

PDAC has blocked another attempted shot: CCTG PA.7 ph2 trial failed to prove benefit adding durva/trem to GemNab. KRAS wt subgroup seems to be good at dribbling against a defensive TME (more data needed).

1

3

20

Tiago Biachi

@BiachiTiago

3 years

Non colorectal GI mini orals today at #esmo21 Fruitful session and amazing discussion with @YJanjigianMD on sintilimab trials in esoph SCC and adeno as well as T-DXd in Western 2nd line HER-2 positive GC @myESMO

1

20

Tiago Biachi

@BiachiTiago

2 years

DANTE ph2 trial: Periop FLOT +/- Atezo in GEA: ✅ 8.5% MSI; 50% PD-L1+, 23% PD-L1 CPS ≥5 ✅ Downsizing (pT0, 23% vs 15%; pN0, 68% vs 54%) ✅ Post-op compl. in 43% ✳️ Promising activity (MATTERHORN ongoing) ✳️ Should we consider trials with all chemo pre-op? @OncoAlert #ASCO22

1

7

18

Tiago Biachi

@BiachiTiago

5 years

I really hope this pandemic resets the world’s priorities.

1

2

19

Tiago Biachi

@BiachiTiago

5 years

Meet the professor at Sirio Libanes Hospital with Andrea Cercek (MSKCC) e our GI team colleagues !

0

19

Tiago Biachi

@BiachiTiago

3 years

The level of complexity we are facing is impressive…

Nature Portfolio

@NaturePortfolio

3 years

A study in @NatureNano finds that tumour cells can hijack mitochondria from immune cells by forming physical nanotubes and suggests that inhibiting this process might represent a potential immunotherapy approach.

2

159

467

0

2

18

Tiago Biachi

@BiachiTiago

5 years

Our paper published today: Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil

Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital...

PURPOSE Despite epidemiologic and molecular differences between esophageal and stomach cancers, most published studies have included patients with either disease in a metastatic scenario. We evalua...

ascopubs.org

0

3

18

Tiago Biachi

@BiachiTiago

4 months

This month we had @lenzgabriel_md from Brazil for observership at @MoffittNews - Academic Visiting Scholar Program! I wish you all the success in this journey about to start! Sure you’ll be a great oncologist!

2

4

17

Tiago Biachi

@BiachiTiago

2 years

HERB ph 2 trial: T-DXd for HER2+ BTC ✅ORR 36.4% ✅PFS 4.4 mo, OS 7.1 mo ✅G≥ 3 in 81.3%, G≥ 3 ILD 12% ✳️HER2 is a target in BTC, T-DXd is active but toxicity was significant; ✳️ ZW25 trial ongoing (NCT04466891) @OncoAlert #ASCO22

0

4

18

Tiago Biachi

@BiachiTiago

4 years

Brain metastases from CRC.. Great job @renata_bonadio

2

1

18

Tiago Biachi

@BiachiTiago

2 years

Congrats @GABOUALFA for this impressive and practice changing trial! Your dedication is really inspiring! Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence

1

18

Tiago Biachi

@BiachiTiago

3 years

If you are a researcher, imagine having an 87% cut in your project budget. This is the size of the budget cut to the Ministry of Science and Technology by the Brazilian government. 87%.

2

1

18

Tiago Biachi

@BiachiTiago

3 months

Looking for a great hands-on course on complex HPB surgery? You just found it! This one is led by faculty from the Moffitt HPB Group and renowned national and international guest faculty. @MoffittNews @MHepatobiliary

1

5

18

Tiago Biachi

@BiachiTiago

2 years

Eisenhower Matrix can help to maintain mental health.

0

5

18

Tiago Biachi

@BiachiTiago

2 years

Good news on biliary tract cancer! Pembro plus chemo improved overall survival in KN-966! #cholangiocarcinoma @MoffittNews

0

18

Tiago Biachi

@BiachiTiago

5 years

Lecturing and sharing experiences about esophageal cancer.. Thank you guys for inviting me to join this event @rcarvalhoonco @Lucasvsmd

0

2

18

Tiago Biachi

@BiachiTiago

4 years

My summary for CRC in #ASCOGI21 1.KN177: Confirmed improvement in OS with pembro (48 vs 33%) and PFS (16 vs 8 mo). Now improved PFS2 (NR vs 23 mo).

1

2

18

Tiago Biachi

@BiachiTiago

2 years

2022 is the year and patients with metastatic #crc are still coming for second opinion with only KRAS tested and no MMR status. This is incredibly sad!

2

17

Tiago Biachi

@BiachiTiago

2 years

Nimotuzumab/CRT for unresectable ESCC -NXCEL1311 ph3 trial: ✅ ORR 93% vs 72% ✅ No OS data yet ✅ G3-5 AEs 11.1% vs.10.9% ✅ No severe skin tox ❇️ Agreed that we buried EFGR too early in ESCC ✳️ Lot to learn how select between EGFR and/or IO combined to CRT @OncoAlert #ASCO22

0

6

17

Tiago Biachi

@BiachiTiago

2 years

PARADIGM ph3 trial: RAS wt mCRC received FOLFOX plus Pmab versus Bev ✅ Pmab improved OS HR 0.84 in ITT and 0.82 in left-sided; ✅ Pmab did not improve PFS (HR 1.01) ✅ Pmab improved RR 75% vs 67% and R0-resec. rate 16 vs 11% BUT ... 👇🏼

1

3

16

Tiago Biachi

@BiachiTiago

7 months

June Rogers Memorial Grand Round at @MoffittNews with Dr Habr-Gama being recognized for developing selective nonoperative treatment for rectal cancer by Dr Leonard Saltz from @MSKCancerCenter @CrcTrialsChat @FightCRC @ColonCancerFdn

0

2

16

Tiago Biachi

@BiachiTiago

1 year

Clinical trials available at @MoffittNews

Clinical Trials at Moffitt

Physicians and researchers work closely together to provide innovative treatment options for patients. Find a trial that is right for you.

www.moffitt.org

0

3

15

Tiago Biachi

@BiachiTiago

2 years

IMPROVE ph2 trial: intermit vs cont Pmab plus FOLFIRI 1L RAS/BRAFwt mCRC ✅PFS 17.6 vs 12.6 mo favoring intermit. group ✅ Less G3-4 tox with intermit(skin 13/27%) ✳️ Consider time off chemo or de-escalate (marathon! not a sprint) ✳️ ctDNA will help to guide @OncoAlert #ASCO22

0

5

15

Tiago Biachi

@BiachiTiago

1 year

Congrats @SteveMaronMD @YJanjigianMD ! Thanks for the opportunity to participate 🙏🏼 @MoffittNews

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

AbstractPurpose:. We report updated clinical outcomes from a phase II study of pembrolizumab, trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric cancer in conjunction with outcomes...

aacrjournals.org

0

14

Tiago Biachi

@BiachiTiago

25 days

Pray for Florida, pray for Tampa Bay Area! Stay safe, keep your families safe, evacuate if asked to do so We will get through this together! #hurricanemilton

NWS Tampa Bay

@NWSTampaBay

25 days

(1/3) Hurricane #Milton Update - 10/7 - 5PM ⚠️If the storm stays on the current track, it will be the worst storm to impact the Tampa area in over 100 years. 🗣️ Please evacuate if told to do so. ⚠️ Complete all prep before tomorrow night #FLwx

31

543

1K

2

1

14

Tiago Biachi

@BiachiTiago

4 years

Better days are coming 🙏🏼 #COVID19

1

0

14

Tiago Biachi

@BiachiTiago

2 years

Thanks France and Argentina for best World Cup final ever!

0

15

Tiago Biachi

@BiachiTiago

4 years

II Brazilian Congress Digestive Cancer: Advances in gastroesophageal cancer In few minutes at

1

0

15

Tiago Biachi

@BiachiTiago

14 days

Heading to Miami for the UM Annual Oncology update! Thanks @GlopesMd for the invitation! @CCAlliance @FightCRC @MoffittNews

2

4

16

Tiago Biachi

@BiachiTiago

1 year

In person @OncLive event in Tampa September 13th: Gastrointestinal Cancer Updates @MoffittNews

1

14

Tiago Biachi

@BiachiTiago

3 years

This year Brazilian Congress of Clinical Oncology is hybrid! Nice section to discuss #gastriccancer and promising targets! @SBOC_Oncologia

0

14

Tiago Biachi

@BiachiTiago

7 months

Come to see @DavidKaldas_MD from @USFNews presenting our poster about MUTYH-CRC cases seen at @MoffittNews revealing an extremely high incidence of targetable alterations: KRAS G12C (24%), MSI-H (17%), BRAF (14%) and BRCA2 (11%)

Abstract 6462: Somatic mutational profile in MUTYH- associated colorectal cancers (MUTYH-CRCs)

Abstract. Background: Biallelic inactivation of MUTYH leads to hereditary predisposition to colorectal polyposis and CRC. Herein we evaluated co-alterations in somatic next-generation sequencing...

aacrjournals.org

1

3

14

Tiago Biachi

@BiachiTiago

3 years

So… should we discuss non-operative management for #MSI #gastriccancer in future trials? #GI22

ASCO

@ASCO

3 years

Neoadjuvant nivo + ipi shows encouraging activity in MSI/dMMR EGJ/gastric adenocarcinoma w/ a pCR rate of 59%, according to study results presented at #GI22 . #ASCODailyNews #GICSM #immunoonc #gionc

0

29

68

2

4

14

Tiago Biachi

@BiachiTiago

1 month

LEADING THE WAY Join us at the Moffitt’s first annual summit on enhancing value in cancer care @MoffittNews

1

2

12

Tiago Biachi

@BiachiTiago

3 years

So honored to represent @MSKCancerCenter at @liverUSA Academic Debates! Thanks @jalpa_devi for sharing presentation and joining us 2AM from Pakistan and @GABOUALFA for mentoring us!

Ghassan Abou-Alfa

@GABOUALFA

3 years

Winning team! Congratulations @MSKCancerCenter @MSK_DeptOfMed @BiachiTiago and @LUMHS_Jamshoro @jalpa_devi for super debate @liverUSA . @GABOUALFA greatly honored to help mentor you both! Impressive @jalpa_devi to join at this late hour 2am in #jamshoro #Pakistan . Thank you team!

0

17

0

1

13

Tiago Biachi

@BiachiTiago

6 months

Massive floods in Brazil’s southern Rio Grande do Sul state (where my family lives) have killed at least 90 people over the last seven days, and another 103 were reported missing, and more 100,000 displaced people from their homes.

1

3

14

Tiago Biachi

@BiachiTiago

2 years

Piece of Brazil on the Upper West side.. Brazilian cheesebread and açaí bowl at #tapNYC

1

0

13

Tiago Biachi

@BiachiTiago

5 months

It’s been a honor to be a FLASCO member supporting it’s mission - advocacy, education and communication. As CRC Captain I hope to help disseminate knowledge and research in CRC, reducing disparities and increasing access. @FLASCO_ORG @MoffittNews @FightCRC @CCAlliance

1

13

Tiago Biachi

@BiachiTiago

2 years

I’ll be discussing most relevant trials on GI Oncology presented at #ASCO22 . Stay tuned to @BrasilOncologia platforms and website.

Oncologia Brasil

@BrasilOncologia

2 years

Dr. Tiago Biachi convida você acompanhar a cobertura de um dos maiores eventos científicos no mundo, que acontecerá entre 3 e 7 de junho! Não perca! Para saber mais acesse: #mdhealth #oncologiabrasil #ASCO22 #oncologia #congresso #sa úde #ci ência

0

1

4

0

3

12

Tiago Biachi

@BiachiTiago

4 years

Thanks for joining us @YJanjigianMD !! Brilliant insights! @sloan_kettering #esophagealcancer #gastriccancer

Yelena Y. Janjigian MD

@YJanjigianMD

4 years

Great case discussion and review of KN181 data by the talented @BiachiTiago #esophagealcancer #Immunotherapy

0

13

1

0

13

Tiago Biachi

@BiachiTiago

5 years

Brazilian Gastric Cancer Association - 20 years.

0

2

13

Tiago Biachi

@BiachiTiago

4 months

Check it out! We discussed liver transplant, immunotherapy, targeted therapies and much more in #colorectalcancer presented at #ASCO24 @MoffittNews

Sameh @ VuMedi

@Sameh_VuMedi

4 months

Check out Dr. Richard Kim & Dr. Tiago Biachi @BiachiTiago @MoffittNews discussing #ASCO24 Key Studies in CRC and their clinical implications (TRANSMET, CheckMate 8HW, NEOPRISM, and PanaMa) Full📽️on #VuMedi 👇 #CRCSM #gicsm #ColorectalCancer

0

2

3

0

3

10

Tiago Biachi

@BiachiTiago

5 months

So well deserved! Congrats!!

Myriam Chalabi

@MyriamChalabi

5 months

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM . Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy . Grateful to the pts and colleagues who made this possible. @HaanenJohn

34

147

564

0

1

12

Tiago Biachi

@BiachiTiago

1 year

Thanks for giving me this opportunity! Ensuring access to high-quality #HCC care for patients worldwide is indispensable! @MoffittNews

Africa Guidelines for Hepatocellular Carcinoma Buildup Process | JCO Global Oncology

PURPOSEHepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic...

ascopubs.org

Ghassan Abou-Alfa

@GABOUALFA

1 year

Hand in hand @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA and colleagues form throughout #Africa : Hepatocellular Carcinoma #HCC #Guidelines Buildup Process for #Africa by #Africa

0

4

12

0

1

12

Tiago Biachi

@BiachiTiago

2 years

Let the games begin! #WorldCup2022

2

0

13

Tiago Biachi

@BiachiTiago

2 years

Ph 3 trial with nimotuzumab plus GEM in 1L for KRAS WT PDAC: ✅ OS 10.9 vs. 8.5 months HR 0.50 ✅ 1yOS 43.6% vs 26.8% ✅ 3yOS 13.9% vs 2.7% Interesting data but.. ❎Outdated backbone ❎What about those BRAFmut /KRASwt PDAC ? #ASCO22 @OncoAlert

0

3

12

Tiago Biachi

@BiachiTiago

2 years

Ph1 trial with CLDN18.2-targeted CAR T cells in GC: ‼️ORR 57%, DCR 75% and 6mo-OS 81% ✅ CLDN 18.2 is definitely a target in GC ✅ CAR T discussion will be part of our routine for most solid tumors in the near future

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Nature Medicine - In an interim analysis of a phase 1 trial, CAR T cells specific for Claudin18.2, a tight junction protein isoform highly expressed on gastrointestinal tract tumors, were...

www.nature.com

0

12